Cite
HARVARD Citation
Child, F. et al. (2016). Phase II multicentre trial of oral quisinostat, a histone deacetylase inhibitor, in patients with previously treated stage IB–IVA mycosis fungoides/Sézary syndrome3. British journal of dermatology. pp. 80-88. [Online].